**CONFIDENTIAL DISCLOSURE AGREEMENT**

This Agreement is made by and between the National Cancer Institute, an agency of the United States Government (hereinafter referred to as "NCI"), and **(insert name of company)**, an entity organized and existing under the laws of **(insert name of state or country)** (hereinafter referred to as “Entity”). Collectively or individually, the NCI and Entity shall also be referred to as “Parties” or “Party.”

WHEREAS, Entity has certain confidential information relating to **(insert Purpose for exchange of information)** (hereinafter referred to as the "Confidential Information"); and

WHEREAS, the NCI is interested in examining the Confidential Information in order to **(insert Purpose for information exchange)**;

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the Parties hereto agree as follows:

1. Entity shall disclose and transmit Confidential Information to the NCI in sufficient detail to enable the NCI to make the determinations set forth above.

2. The NCI agrees to accept the Confidential Information and employ all reasonable efforts to maintain the Confidential Information of Entity secret and confidential, such efforts to be no less than the degree of care employed by the NCI to preserve and safeguard its own confidential information. The Confidential Information shall not be disclosed, revealed, or given to anyone by the NCI except individuals working on behalf of NCI who are under an obligation of confidentiality to the receiving Party and who have a need to review the Confidential Information in connection with the NCI's evaluation. Such individuals shall be advised by the NCI of the confidential nature of the Confidential Information and that the Confidential Information shall be treated accordingly.

3. The Entity hereby acknowledges that the NCI shall not incur any liability merely for examining and considering the Confidential Information; however, the NCI agrees that it will not use the Confidential Information for any purpose except as set forth herein.

4. The NCI's obligations under Paragraph 2 and 3 above shall not extend to any part of the Confidential Information of the Entity:

(a) that can be demonstrated to have been in the public domain or publicly known at the time of disclosure; or

(b) that can be demonstrated to have been in the NCI’s possession or that can be demonstrated to have been readily available to the NCI from another source prior to the disclosure; or

(c) that becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized act by the NCI; or

(d) that can be demonstrated as independently developed or acquired by the NCI without reference to or reliance upon such Confidential Information; or

(e) that is required to be disclosed by law.

5. The NCI's obligations under Paragraphs 2 and 3 shall extend for a period of five (5) years from the date of the last signature to this Agreement

6. All information to be deemed confidential under this Agreement shall be clearly marked "**CONFIDENTIAL**" by Entity. Any Confidential Information which is orally disclosed must be reduced to writing and marked "**CONFIDENTIAL**" by Entity and such notice must be provided to the NCI within thirty (30) days of such disclosure.

7. It is understood that nothing herein shall be deemed to constitute, by implication or otherwise, the grant to the NCI of any license or other rights under any patent, patent application or other intellectual property right or interest belonging to Entity.

8. It is understood and agreed by both Parties that each represents and warrants to the other Party that each Official signing this Agreement has authority to do so.

9. The illegality or invalidity of any provision of this Agreement shall not impair, affect or invalidate the other provisions of this Agreement.

10. The construction, validity, performance and effect of this Agreement shall be governed by Federal law, as applied by the Federal Courts in the District of Columbia.

11. The term of this Agreement is two (2) years from the date of the last signature to this Agreement. Section 5 shall survive the termination for the period provided therein. The Agreement may be terminated at any time by either Party, with thirty (30) days written notice. The term may be extended and the provisions of this Agreement may be modified only by written amendment signed by the duly authorized signatory for each Party.

 **SIGNATURES BEGIN ON THE FOLLOWING PAGE**

 **ACCEPTED AND AGREED**

*The undersigned expressly certify or affirm that the contents of any statements made or reflected in this document are truthful and accurate. The undersigned further agree to examine and consider the subject matter of the Confidential Information on the foregoing basis.*

**FOR THE NATIONAL CANCER INSTITUTE**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Jason Cristofaro, J.D., Ph.D. Date

CTEP Alternate Technology Development Coordinator

Please address all correspondence related to this agreement to Sally Hausman at the following address:

Sally Hausman

Regulatory Affairs Branch

Cancer Therapy Evaluation Program

9609 Medical Center Drive, Rm. 5W-530

Rockville, MD 20850

e-mail: hausmans@ctep.nci.nih.gov

Phone: 240-276-6124

**FOR THE ENTITY**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(Authorized Signatory for Entity) Date

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(Printed Name)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(Title of Signatory)

Address:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_